Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention

Award Number: R01HD110109
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/09/2023
PERIOD OF PERFORMANCE END DATE: 07/31/2028

Group Awards By:

View Award Description

OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention - Project Summary The primary goal of this proposal is to fill critical gaps related to timing, route and dose of tranexamic acid (TXA) in prevention of postpartum hemorrhage (PPH) to maximize maternal benefit while minimizing fetal-neonatal and maternal risks. With my clinical background in Maternal-Fetal Medicine, research experiences in epidemiologic and translational coagulation methods, and prior preliminary data, I have the expertise and strong scientific premise to successfully complete these aims. The proposed innovative study focuses on three unique subpopulations (vaginal delivery, cesarean delivery, morbid obesity) and has three routes of TXA administration (intravenous over 2 minutes, intravenous over 10 minutes and intramuscular) immediately prior to childbirth. Neonatal exposure will be assessed through TXA concentrations in umbilical cord blood and breast milk, as well as clinical outcomes at delivery, 2 weeks and 6 weeks postpartum. The specific aims are as follows: 1a) Determine the optimal timing, route and dose of prophylactic TXA for prevention of PPH 1b) Determine neonatal exposure to TXA through transplacental transfer and breast milk when TXA is administered pre-cord clamp, and 2) Characterize prothrombotic and fibrinolytic biomarkers in maternal circulation following TXA. The innovative nature of this grant is multifold: a) repurposing an inexpensive generic drug to address disparities in obstetric hemorrhage; b) exploring rapid administration via IM and 2min infusion to improve access in low resource settings; c) pre-cord clamp TXA administration as a novel approach not yet considered in large obstetric clinical trials; d) refinement of dosing in unique subpopulations (morbidly obese, vaginal delivery); e) biomarker safety including a no drug group and f) a robust team of multidisciplinary experts with regional and international expertise. Specifically, team members have expertise in clinical pharmacology, neonatal medicine, lab medicine, thrombosis and hemostasis, clinical trials in pregnant women and newborns, pharmacometrics and epidemiology/biostatistics. I have an ideal working environment, rooted in the Clinical and Translational Science Institute partnering GW and Children’s National Hospital but also extended through supplemental sites at University of Maryland Center for Translational Medicine and University of North Carolina Coagulation Lab. In summary, this proposal sets forth aims that are significant, innovative, feasible, and will help the obstetric community better understand how peripartum hemostasis can be optimized using TXA while being sure to minimize fetal/neonatal risks. Ultimately, our work will answer important questions that are part of the solution for how to prevent maternal morbidity and mortality for the 140 million women worldwide that give birth each year.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $582,131 )
2025	2025	INOVA HEALTH CARE SERVICES	8095 INNOVATION PARK DR	FAIRFAX	VA	22031	FAIRFAX	USA	Child Health and Human Development Extramural Research	000	4	9/3/2025	NON-COMPETING CONTINUATION	$582,131
														Subtotal = $582,131

Issue Date FY: 2024 ( Subtotal = $546,173 )
2024	2024	INOVA HEALTH CARE SERVICES	8095 INNOVATION PARK DR	FAIRFAX	VA	22031	FAIRFAX	USA	Child Health and Human Development Extramural Research	003	3	7/29/2024	NON-COMPETING CONTINUATION	$556,408
2024	2023	INOVA HEALTH CARE SERVICES	8095 INNOVATION PARK DR	FAIRFAX	VA	22031	FAIRFAX	USA	Child Health and Human Development Extramural Research	002	2	3/7/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2024	2023	INOVA HEALTH CARE SERVICES	8095 INNOVATION PARK DR	FAIRFAX	VA	22031	FAIRFAX	USA	Child Health and Human Development Extramural Research	001	2	1/3/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$571,020
2024	2023	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Child Health and Human Development Extramural Research	000	1	1/3/2024	NEW	-$581,255
														Subtotal = $546,173

Issue Date FY: 2023 ( Subtotal = $581,255 )
2023	2023	GEORGE WASHINGTON UNIVERSITY (THE)	1918 F ST NW	WASHINGTON	DC	20052	DISTRICT OF COLUMBIA	USA	Child Health and Human Development Extramural Research	000	1	8/9/2023	NEW	$581,255
														Subtotal = $581,255

Grand Total All Awards = $1,709,559

Top

All Categories

About

Search

Reports

Data Submission

Award Information

OPTIMUM OB-TXA: Optimal TIMing, route and dose of tranexamic acid prior to UMbilical cord clamp for postpartum hemorrhage prevention

Award Number: R01HD110109

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/09/2023

PERIOD OF PERFORMANCE END DATE: 07/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer